NCT06241742 is a Phase 2 clinical trial of HT-6184 in Pain, sponsored by Halia Therapeutics, Inc..

Who is sponsoring NCT06241742?

NCT06241742 is sponsored by Halia Therapeutics, Inc..

What drugs are being tested in NCT06241742?

Interventions in NCT06241742: HT-6184, HT-6184 Placebo.

Is NCT06241742 still recruiting?

NCT06241742 is currently completed. Last updated 30 March 2025.

Last reviewed 2025-03-30 · How we verify

NCT06241742

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

Completed Phase 2 Last updated 30 March 2025

What this trial tests

Phase 2 trial testing HT-6184 in Pain in 81 participants. Completed in 30 April 2024.

Timeline

12 February 2024

Primary endpoint
30 April 2024

30 April 2024

Quick facts

Lead sponsor	Halia Therapeutics, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	81
Start date	12 February 2024
Primary completion	30 April 2024
Estimated completion	30 April 2024
Sites	1 location across United States

Drugs / interventions tested

HT-6184 — full drug profile →
HT-6184 Placebo

Conditions studied

Pain — all drugs for Pain →

Sponsor

Halia Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal. The main question it aims to answer are: * Does HT-6184 decrease inflammation in patients after third molar removal? * Does HT-6184 decrease pain in patients after third molar removal? Participants will be asked to do the following during the clinical trial: * Take a single oral dose of HT-6184 or placebo * Allow a oral surgeon remove their third molar teeth * Blood draws on 5 occurrences * Rate their pain intensity * Attend two follow-up appointments on day 1 and day 2 after third molar removal * Participate in one follow-up phone call 5-7 days after third molar removal

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the NLRP3 inflammasome for inflammatory disease therapy.
Cabral JE, Wu A, Zhou H, Pham MA, et al · · 2025 · cited 57× · PMID 40374417 · DOI 10.1016/j.tips.2025.04.007
Chronic Pain: Epidemiology, Pathophysiology, and Clinical Management.
Shang Z, Tian Z, Wang Z, Yang Z, et al · · 2026 · PMID 42100792 · DOI 10.1002/mco2.70756

Verify or expand the search:

Other trials of HT-6184

Trials testing the same drug.

NCT07172867 — A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM · Phase 2 · withdrawn
NCT07052006 — A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia · Phase 2 · active not recruiting
NCT05447546 — Study to Evaluate HT-6184 in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Other Halia Therapeutics, Inc. trials

Trials by the same sponsor.

NCT07399171 — Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers · Phase 2 · not yet recruiting
NCT07172867 — A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM · Phase 2 · withdrawn
NCT06537817 — Study to Evaluate HT-4253 in Healthy Subjects · Phase 1 · completed
NCT07052006 — A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia · Phase 2 · active not recruiting
NCT05447546 — Study to Evaluate HT-6184 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06241742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Halia Therapeutics, Inc.
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06241742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing